Burning Rock Biotech (BNR) Liabilities and Shareholders Equity (2019 - 2026)

Burning Rock Biotech's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $114.2 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 3.04% year-over-year to $114.2 million; the TTM figure through Mar 2026 stood at $459.1 million (down 12.08% YoY), while the FY2025 annual figure was $115.7 million, down 4.63% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $114.2 million, down from $115.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $332.5 million in Q1 2022, with the low at $114.1 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $140.8 million (2024), against an average of $169.9 million.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity plunged 37.93% in 2023, then dropped 3.04% in 2026.
• Burning Rock Biotech's Liabilities and Shareholders Equity stood at $223.2 million in 2022, then slumped by 35.29% to $144.4 million in 2023, then slipped by 14.67% to $123.2 million in 2024, then decreased by 6.15% to $115.7 million in 2025, then retreated by 1.26% to $114.2 million in 2026.
• Business Quant data shows BNR's Liabilities and Shareholders Equity at $114.2 million in Q1 2026, $115.7 million in Q4 2025, and $114.1 million in Q3 2025.